LEXICON PHARMACEUTICALS, INC. (LXRX) - Dilution Analysis

10-Q filing | 400.2M shares outstanding

8-K filing: Lexicon Pharmaceuticals, Inc. entered into a loan and security agreement with Hercules Capital, Inc. and granted Hercules warrants to purchase 691,823 shares of its common stock at an exercise price of $1.59 per share concurrent with the funding of the first tranche.

10-Q filing | 363.4M shares outstanding

10-Q filing | 362.1M shares outstanding

10-K filing | 361.5M shares outstanding

10-Q filing | 361.5M shares outstanding

S-3 filing: The filing relates to a shelf offering of securities, including common stock, potentially involving rights offerings to stockholders and standby underwriting agreements.

10-Q filing | 361.5M shares outstanding

S-3/A filing: This prospectus relates to the proposed offer and resale by selling stockholders of up to 57,661,250 shares of common stock.

8-K filing: On May 10, 2024, 2,304,147 shares of Series A Convertible Preferred Stock were converted into 115,207,350 shares of common stock, and the company filed a Sixth Amended and Restated Certificate of Incorporation, increasing the number of authorized Common Stock shares from 300,000,000 to 450,000,000.

10-Q filing | 245.4M shares outstanding

10-K filing | 246.2M shares outstanding

S-3 filing: This prospectus relates to the proposed offer and resale by selling stockholders of shares of our common stock to be issued by us directly to the selling stockholders identified in this prospectus.

10-Q filing | 244.9M shares outstanding

10-Q filing | 244.9M shares outstanding

10-Q filing | 189.0M shares outstanding

10-K filing | 188.7M shares outstanding

10-Q filing | 174.9M shares outstanding

10-Q filing | 183.6M shares outstanding

10-Q filing | 149.2M shares outstanding

8-K filing: Lexicon granted Oxford Finance LLC a warrant to purchase 420,673 shares of Lexicon's common stock at an exercise price of $2.08 per share in connection with a loan and security agreement.

10-K filing | 106.2M shares outstanding

10-Q filing | 145.8M shares outstanding

S-3 filing: Lexicon Pharmaceuticals, Inc. is filing an S-3 to register an indeterminate number of common stock, preferred stock, debt securities, warrants, and rights with an aggregate initial offering price not to exceed $200,000,000.

10-Q filing | 144.5M shares outstanding

10-Q filing | 143.4M shares outstanding

8-K filing: Stockholders approved an amendment to the 2017 Non-Employee Directors' Equity Incentive Plan increasing the total number of shares of common stock issuable under the plan from 600,000 to 1,200,000; a Second Amended and Restated Certificate of Incorporation was filed granting preemptive and consent rights to holders of 20% or more of outstanding common stock.

10-K filing | 144.4M shares outstanding

10-Q filing | 117.6M shares outstanding

8-K filing: Lexicon Pharmaceuticals, Inc. exchanged $13.25 million aggregate principal amount of its outstanding 5.25% Convertible Senior Notes due 2021 for 1,622,838 shares of the Company's common stock and $8.98 million in cash.

8-K filing: Lexicon Pharmaceuticals exchanged $62.55 million of convertible notes for 8,746,117 shares of common stock and $41.03 million in cash.

10-Q filing | 107.1M shares outstanding

10-Q filing | 106.5M shares outstanding

10-K filing | 116.7M shares outstanding